

REFERENCES

- [1] Ray S, Sonthalia N, Kundu S, Ganguly S, “Autoimmune disorders: an Overview of molecular and cellular basis in today’s perspective”, J Clin Cell Immunol, 2012, doi: 10.4172/2155-9899.S10-003
- [2] The autoimmune disease coordinating committee, “Progress in autoimmune disease”, National Institute of health, 2005, Available from: [www.niaid.nih.gov /topics/autoimmune/ Documents /adccfinal.pdf](http://www.niaid.nih.gov/topics/autoimmune/Documents/adccfinal.pdf)
- [3] Fairweather D, “Autoimmune Disease: Mechanisms,” Encyclopedia of life sciences, 2007, doi: 10.1002/9780470015902.a0020193
- [4] Kidd P, “Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease,” Altern Med Rev, 2003, 8(3), 223-46.
- [5] Ishida H, Ota H, Yanagida H, Dobashi H, “An imbalance between Th1 and Th2-like cytokines in patients with autoimmune diseases-- differential diagnosis between Th1 dominant autoimmune diseases and Th2 dominant autoimmune diseases,” Nihon Rinsho, 1997, 55(6), 1438-43.
- [6] Noack M, Miossec P, “Th17 and regulatory T cell balance in autoimmune and inflammatory diseases,” Autoimmun Rev, 2014, 13(6), 668-77.
- [7] Korn T, Oukka M, Kuchroo V, Bettelli E, “ Th7 cells: Effector T cell with inflammatory properties,” Semin Immuno, 2007, 19(6), 362-71.
- [8] Miossec P, Korn T, Kuchroo VK, “Interleukin-17 and type 17 helper T cells,” N Engl J Med, 2009, 361(9), 888-98.

- [9] Wilke CM, Bishop K, Fox D, Zou W, "Deciphering the role of Th17 cells in human disease," Trends Immunol, 2011, 32(12), 603-11.
- [10] Vincent FB, Northcott M, Hoi A, Mackay F, Morand EF, "Clinical associations of serum interleukin-17 in systemic lupus erythematosus," Arthritis Res Ther, 2013, 15(4), R97.
- [11] Zhao XF, Pan HF, Yuan H, Zhang WH, Li XP, Wang GH, *et al.*, "Increased serum interleukin 17 in patients with systemic lupus erythematosus," Mol Biol Rep, 2010, 37(1): 81-5.
- [12] Zickert A, Amoudruz P, Sundström Y, Rönnelid J, Malmström V, Gunnarsson I, "IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment. BMC Immunology," 2015, doi: 10.1186/s12865-015-0070-7
- [13] Zhou L, Lopes JE, Chong MM, Ivanov, II, Min R, Victora GD, *et al.*, "TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function," Nature, 2008, 453(7192), 236-40.
- [14] Moir S, Fauci AS, "Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease," J Allergy Clin Immunol, 2008, 122(1), 12-9.
- [15] Abbas AK, Lichtman AH, *Basic Immunology: Functions and Disorders of the Immune System*, 3rd ed, Elsevier health science, 2009.
- [16] Sompayrac L, *How the immune system work*, 4th ed, John Wiley & Sons, 2012.
- [17] Bellone M, "Autoimmune Disease:Pathogenesis," Encyclopedia of life sciences, 2005, doi: 10.1038/npg.els.004000
- [18] Oldstone MB, "Molecular mimicry and immune-mediated diseases," FASEB J, 1998, 12(13), 1255-65.

- [19] von Muhlen CA, Tan EM, “Autoantibodies in the diagnosis of systemic rheumatic diseases,” *Semin Arthritis Rheum*, 1995, 24(5), 323-58.
- [20] The autoimmune disease coordinating committee, “Autoimmune disease reasearch plan,” HHIH publication, 2002, Available from: www.niaid.nih.gov/topics/autoim-mune/documents/adccreport.pdf
- [21] Dooley MA, Hogan SL, “Environmental epidemiology and risk factors for autoimmune disease,” *Curr Opin Rheumatol*, 2003,15(2), 99-103.
- [22] Salamunić I, “Laboratory diagnosis of autoimmune diseases – new technologies, old dilemmas,” *Biochemia Medica*, 2010, 20(1), 45-56.
- [23] Feldt J, “Antinuclear Antibodies (ANA),” *American College of Rheumatology*, 2012, Available from: [www.rheumatology.org/Practice/Clinical/Patients/Diseases_And_Conditions/Antinuclear_Antibodies_\(ANA\)](http://www.rheumatology.org/Practice/Clinical/Patients/Diseases_And_Conditions/Antinuclear_Antibodies_(ANA))
- [24] Wandstrat AE, Carr-Johnson F, Branch V, Gray H, Fairhurst AM, Reimold A, *et al.*, “Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus,” *J Autoimmun*, 2006, 27(3), 153-60
- [25] Hu J, Meng W, Zhang D, Qiu C, Hua L, Xie Q, *et al.*, “Th17-relevant cytokines vary with sera of different ANA staining patterns,” *Int Immunopharmacol*, 2013, 15(4), 679-84.
- [26] Tozzoli R, Bizzaro N, Tonutti E, Villalta D, Bassetti D, Manoni F *et al.*, “Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic diseases,” *Am J Clin Pathol*, 2002, 117(2), 316-24.
- [27] Migliorini P, Baldini C, Rocchi V, Bombardieri S, “Anti-Sm and anti-RNP antibodies,” *Autoimmunity*, 2005, 38(1), 47-54.
- [28] Rokeach LA, Hoch SO, “B-cell epitopes of Sm autoantigens,” *Mol Biol Rep*, 1992, 16(3), 165-74.

- [29] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum.* 1997; 40(9): 1725.
- [30] Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, *et al.*, “The 1982 revised criteria for the classification of systemic lupus erythematosus,” *Arthritis Rheum*, 1982, 25(11), 1271-7.
- [31] Tanimoto K, Nakano K, Kano S, Mori S, Ueki H, Nishitani H, *et al.*, “Classification criteria for polymyositis and dermatomyositis *J Rheumatol*,” 1995, 22(4), 668-74.
- [32] LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, *et al.*, “Scleroderma (systemic sclerosis): classification, subsets and pathogenesis,” *J Rheumatol*, 1988, 15(2), 202-5.
- [33] Amigues JM, Cantagrel A, Abbal M, Mazieres B, “Comparative study of 4 diagnosis criteria sets for mixed connective tissue disease in patients with anti-RNP antibodies. Autoimmunity Group of the Hospitals of Toulouse,” *J Rheumatol*, 1996, 23(12), 2055-62.
- [34] Kumar Y, Bhatia A, Minz RW, “Antinuclear antibodies and their detection methods in diagnosis of connective tissue diseases: a journey revisited,” *Diagn Pathol*, 2009, 4(1), doi:10.1186/1746-1596-4-1.
- [35] Tang L, Benjaponpitak S, DeKruyff RH, Umetsu DT, “Reduced prevalence of allergic disease in patients with multiple sclerosis is associated with enhanced IL-12 production” *J Allergy Clin Immunol*, 1998, 102(3), 428-35.
- [36] Gerli R, Bistoni O, Russano A, Fiorucci S, Borgato L, Cesarotti ME, *et al.*, “In vivo activated T cells in rheumatoid synovitis. Analysis of Th1- and Th2-type cytokine production at clonal level in different stages of disease” *Clin Exp Immunol*, 2002, 129(3), 549-55.

- [37] Chang DM, Su WL, Chu SJ, "The expression and significance of intracellular T helper cytokines in systemic lupus erythematosus," *Immunol Invest*, 2002, 31(1), 1-12.
- [38] Akahoshi M, Nakashima H, Tanaka Y, Kohsaka T, Nagano S, Ohgami E, *et al.*, "Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus." *Arthritis Rheum*, 1999, 42(8), 1644-8.
- [39] Korn T, Bettelli E, Oukka M, Kuchroo VK, "IL-17 and Th17 cells," *Annual Review of Immunology*, 2009, 27, 485-517.
- [40] Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL, "Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17," *J Biol Chem*, 2003, 278(3), 1910-4.
- [41] Kolls JK, Linden A, "Interleukin-17 family members and inflammation," *Immunity*, 2004, 21(4), 467-76.
- [42] Moseley TA, Haudenschild DR, Rose L, Reddi AH, "Interleukin-17 family and IL-17 receptors," *Cytokine Growth Factor Rev*, 2003, 14(2), 155-74.
- [43] Awasthi A, Kuchroo VK, "Th17 cells: from precursors to players in inflammation and infection" *Int Immunol*, 2009, 21(5), 489-98.
- [44] Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW, "Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in autoimmunity" *Clin Immunol*, 2008, 127(3), 385-93.
- [45] Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, *et al.*, "Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus," *Nat Immunol*, 2009, 10(7), 778-85.

- [46] Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, *et al.*, "Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort)" *Arthritis Rheum*, 2006, 54(4), 1122-31.
- [47] Matuskevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, Fredrikson S, *et al.* "Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis," *Mult Scler*, 1999, 5(2), 101-4.
- [48] Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, *et al.* "A genome-wide association study identifies IL23R as an inflammatory bowel disease gene," *Science*, 2006, 314(5804), 1461-3.
- [49] Zambrano-Zaragoza JF, Romo-Martinez EJ, Duran-Avelar Mde J, Garcia-Magallanes N, Vibanco-Perez N, "Th17 cells in autoimmune and infectious diseases" *Int J Inflam*, 2014, doi: 10.1155/2014/651503.
- [50] Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, *et al.* "Transforming growth factor-beta induces development of the T(H)17 lineage," *Nature*, 2006, 441(7090), 231-4.
- [51] Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B, "TGF beta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells," *Immunity*, 2006, 24(2), 179-89.
- [52] Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, *et al.* "IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways," *Nat Immunol*, 2007, 8(9), 967-74.
- [53] Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, *et al.*, "Essential autocrine regulation by IL-21 in the generation of inflammatory T cells," *Nature*, 2007, 448(7152), 480-3.

- [54] Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, *et al.*, “Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation,” *J Exp Med*, 2003, 198(12), 1951-7.
- [55] Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, *et al.*, “Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain,” *Nature*, 2003, 421(6924), 744-8.
- [56] Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, *et al.* “IL-21 and TGF-beta are required for differentiation of human T(H)17 cells,” *Nature*, 2008, 454(7202), 350-2.
- [57] Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgamma. *Nat Immunol*. 2008; 9(6): 641-9.
- [58] Gershon RK, “A disquisition on suppressor T cells” *Transplant Rev*, 1975, 26, 170-85.
- [59] Ahmadzadeh M, Felipe-Silva A, Heemskerk B, Powell DJ Jr, Wunderlich JR, Merino MJ, *et al.*, “FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions” *Blood*, 2008, 112(13), 4953-60.
- [60] Hori S, Nomura T, Sakaguchi S, “Control of regulatory T cell development by the transcription factor Foxp3,” *Science*, 2003, 299(5609), 1057-61.
- [61] Fontenot JD, Rudensky AY, “A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3,” *Nat Immunol*, 2005, 6(4), 331-7.

- [62] Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, *et al.*, “CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4⁺ T reg cells,” *J Exp Med*, 2006, 203(7), 1701-11.
- [63] Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, *et al.*, “Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells,” *J Exp Med*, 2006, 203(7), 1693-700.
- [64] Ziegler SF, “FOXP3 of mice and men,” *Annu Rev Immunol*, 2006, 24, 209-26.
- [65] Sakaguchi S, “Naturally arising CD4⁺ regulatory t cells for immunologic self-tolerance and negative control of immune responses,” *Annu Rev Immunol*, 2004, 22, 531-62.
- [66] Verdonk RC, Haagsma EB, Jonker MR, Bok LI, Zandvoort JH, Kleibeuker JH, *et al.*, “Effects of different immunosuppressive regimens on regulatory T-cells in noninflamed colon of liver transplant recipients,” *Inflamm Bowel Dis*, 2007, 13(6), 703-9.
- [67] Mills KH, “Regulatory T cells: friend or foe in immunity to infection?,” *Nat Rev Immunol*, 2004, 4(11), 841-55.
- [68] Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, *et al.*, “Conversion of peripheral CD4⁺CD25⁻ naive T cells to CD4⁺CD25⁺ regulatory T cells by TGF-beta induction of transcription factor Foxp3,” *J Exp Med*, 2003, 198(12), 1875-86.
- [69] Pasare C, Medzhitov R, “Toll pathway-dependent blockade of CD4⁺CD25⁺ T cell-mediated suppression by dendritic cells,” *Science*, 2003, 299(5609), 1033-6.
- [70] Stratton R, Slapak G, Mahungu T, Kinloch-de Loes S, “Autoimmunity and HIV,” *Curr Opin Infect Dis*, 2009, 22(1), 49-56.

- [71] Rawson PM, Molette C, Videtta M, Altieri L, Franceschini D, Donato T, *et al.*, “Cross-presentation of caspase-cleaved apoptotic self antigens in HIV infection,” *Nat Med*, 2007, 13(12), 1431-9.
- [72] Rowland-Jones S, Dong T, “Dying T cells trigger autoimmunity in HIV,” *Nat Med*, 2007, 13(12), 1413-5.
- [73] Gisele Zandman-Goddard YS, “HIV and autoimmunity,” *Autoimmunity Reviews*, 2002.
- [74] Massabki PS, Accetturi C, Nishie IA, da Silva NP, Sato EI, Andrade LE, “Clinical implications of autoantibodies in HIV infection,” *AIDS*, 1997, 11(15), 1845-50.
- [75] Arguello RJ, Balbaryski J, Barboni G, Candi M, Gaddi E, Laucella S, “Altered frequency and phenotype of CD4⁺ forkhead box protein 3⁺ T cells and its association with autoantibody production in human immunodeficiency virus-infected paediatric patients,” *Clin Exp Immunol*, 2012, 168(2), 224-33.
- [76] Iordache L, Launay O, Bouchaud O, Jeantils V, Goujard C, Boue F, *et al.*, “Autoimmune diseases in HIV-infected patients: 52 cases and literature review,” *Autoimmun Rev*, 2014, 13(8), 850-7.
- [77] Stahl D, Lacroix-Desmazes S, Misra N, Karmochkine M, Kaveri SV, Costagliola D, *et al.*, “Alterations of self-reactive antibody repertoires in HIV disease: an insight into the role of T cells in the selection of autoreactive B cells,” *Immunol Lett*, 2005, 99(2), 198-208.
- [78] Tsiakalos A, Routsias JG, Kordossis T, Moutsopoulos HM, Tzioufas AG, Sipsas NV, “Fine epitope specificity of anti-erythropoietin antibodies reveals molecular mimicry with HIV-1 p17 protein: a pathogenetic mechanism for HIV-1-related anemia,” *J Infect Dis*, 2011, 204(6), 902-11.

- [79] Martinez V, Diemert MC, Braibant M, Potard V, Charuel JL, Barin F, *et al.*, “Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation,” *Clin Infect Dis*, 2009, 48(1), 123-32.
- [80] Savige JA, Chang L, Horn S, Crowe SM, “Anti-nuclear, anti-neutrophil cytoplasmic and anti-glomerular basement membrane antibodies in HIV-infected individuals,” *Autoimmunity*, 1994, 18(3), 205-11.
- [81] Favre D, Lederer S, Kanwar B, Ma ZM, Proll S, Kasakow Z, *et al.*, “Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection,” *PLoS Pathog*, 2009, 5(2), e1000295.
- [82] Favre D, Mold J, Hunt PW, Kanwar B, Loke P, Seu L, *et al.*, “Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease,” *Sci Transl Med*, 2010, 2(32), 32-6.
- [83] Guenova E, Skabytska Y, Hoetzenecker W, Weindl G, Sauer K, Tham M, *et al.*, “IL-4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells (supporting information),” *Proc Natl Acad Sci U S A*, 2015, 112(7), 2163-8.
- [84] Ercolini AM, Miller SD, “The role of infections in autoimmune disease,” *Clin Exp Immunol*, 2009, 155(1), 1-15.
- [85] Kulthanan K, Jiamton S, Omcharoen V, Linpiyawan R, Ruangpeerakul J, Sivayathorn A, “Autoimmune and rheumatic manifestations and antinuclear antibody study in HIV-infected Thai patients,” *International journal of dermatology*, 2002, 41(7), 417-22.

- [86] Krishnan K, Panchapakesa C, Porkodi R, Madhavan R, Santh G, Mahesh A, "Rheumatological manifestations in hiv positive patients referred to a tertiary care centre," J Indian Rheumatol Assoc, 2003, 11(1), 104 - 8.
- [87] de Vlam K, De Keyser F, Verbruggen G, Vandenbossche M, Vanneuville B, D'Haese D, *et al.*, "Detection and identification of antinuclear autoantibodies in the serum of normal blood donors," Clinical and experimental rheumatology, 1993, 11(4), 393-7.
- [88] Fernandez SA, Lobo AZ, Oliveira ZN, Fukumori LM, AM Pr, Rivitti EA, "Prevalence of antinuclear autoantibodies in the serum of normal blood donors," Revista do Hospital das Clinicas, 2003, 58(6), 315-9.
- [89] Guo YP, Wang CG, Liu X, Huang YQ, Guo DL, Jing XZ, *et al.*, "The prevalence of antinuclear antibodies in the general population of china: a cross-sectional study," Current therapeutic research, clinical and experimental, 2014, 76, 116-9.
- [90] Sankar J, Raj D, Sankar J, Sharma PK, Lodha R, Kabra SK, "HIV infection mimicking autoimmune disorder," Indian journal of pediatrics" 2007, 74(8), 777-80.
- [91] Kaliyadan F, "Hiv and lupus erythematosus: a diagnostic dilemma," Indian journal of dermatology, 2008, 53(2), 80-2.
- [92] Baig MM, Shere SJ, "Prevalence of autoantibodies in Saudi population," Journal of medicine, 1989, 20(3-4), 286-90.
- [93] Manoussakis MN, Tzioufas AG, Silis MP, Pange PJ, Goudevenos J, Moutsopoulos HM, "High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population," Clin Exp Immunol, 1987, 69(3), 557-65.

- [94] Goemaere S, Ackerman C, Goethals K, De Keyser F, Van der Straeten C, Verbruggen G, *et al.*, "Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition," *J Rheumatol*, 1990, 17(12), 1620-2.
- [95] Azizah MR, Shahnaz M, Zulkifli MN, Nasuruddin BA, "Anti-nuclear, anti-mitochondrial, anti-smooth muscle and anti-parietal cell antibodies in the healthy Malaysian population," *The Malaysian journal of pathology*, 1995, 17(2), 83-6.
- [96] Lahita RG, "Sex steroids and the rheumatic diseases," *Arthritis Rheum.* 1985, 28(2), 121-6.
- [97] Makinodan T, Kay MM, "Age influence on the immune system," *Adv Immunol*, 1980, 29, 287-330.
- [98] Gresh JP, Aquilar JL, Espinoza LR, "Human immunodeficiency virus (HIV) infection-associated dermatomyositis," *J Rheumatol*, 1989, 16(10) 1397-8.
- [99] Baguley E, Wolfe C, Hughes GR, "Dermatomyositis in HIV infection," *British journal of rheumatology*, 1988, 27(6), 493-4.
- [100] Daikh BE, Holyst MM, "Lupus-specific autoantibodies in concomitant human immunodeficiency virus and systemic lupus erythematosus: case report and literature review," *Semin Arthritis Rheum.* 2001, 30(6), 418-25.
- [101] de Clerck LS, Couttenye MM, de Broe ME, Stevens WJ, "Acquired immunodeficiency syndrome mimicking Sjogren's syndrome and systemic lupus erythematosus," *Arthritis Rheum*, 1988, 31(2), 272-5.
- [102] Kudva YC, Peterson LS, Holley KE, Wright AJ, Hunder GG, "SLE nephropathy in a patient with HIV infection: case report and review of the literature," *J Rheumatol*, 1996, 23(10), 1811-5.

- [103] Contreras G, Green DF, Pardo V, Schultz DR, Bourgoignie JJ, “Systemic lupus erythematosus in two adults with human immunodeficiency virus infection, *Am J Kidney Dis*, 1996, 28(2), 292-5.
- [104] Klatt NR, Brenchley JM, “Th17 cell dynamics in HIV infection,” *Current opinion in HIV and AIDS*, 2010, 5(2), 135-40.
- [105] Valverde-Villegas JM, Matte MC, de Medeiros RM, Chies JA, “New Insights about Treg and Th17 Cells in HIV Infection and Disease Progression,” *Journal of immunology research*, 2015, 2015: 647916.
- [106] DaFonseca S, Niessl J, Pouvreau S, Wacleche VS, Gosselin A, Cleret-Buhot A, *et al.*, “Impaired Th17 polarization of phenotypically naïve CD4(+) T-cells during chronic HIV-1 infection and potential restoration with early ART, *Retro-virology*, 2015, 12:38.
- [107] Montes M, Sanchez C, Lewis DE, Graviss EA, Seas C, Gotuzzo E, *et al.*, “Normalization of FoxP3(+) regulatory T cells in response to effective antiretroviral therapy,” *J Infect Dis*, 2011, 203(4), 496-9.
- [108] Rueda CM, Velilla PA, Chougnet CA, Rugeles MT, “Incomplete normalization of regulatory t-cell frequency in the gut mucosa of Colombian HIV-infected patients receiving long-term antiretroviral treatment,” *PLoS One*, 2013, 8(8), e71062.
- [109] Mendez-Lagares G, Pozo-Balado MM, Genebat M, Garcia Perganeda A, Leal M, Pacheco YM, “Severe immune dysregulation affects CD4(+)CD25(hi) FoxP3(+) regulatory T cells in HIV-infected patients with low-level CD4 T-cell repopulation despite suppressive highly active antiretroviral therapy,” *J Infect Dis*, 2012, 205(10), 1501-9.
- [110] Piconi S, Trabattoni D, Gori A, Parisotto S, Magni C, Meraviglia P, *et al.*, “Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy,” *AIDS*, 2010, 24 (13), 1991-2000.

- [111] Ndhlovu LC, Chapman JM, Jha AR, Snyder-Cappione JE, Pagan M, Leal FE, *et al.*, “Suppression of HIV-1 plasma viral load below detection preserves IL-17 producing T cells in HIV-1 infection, *AIDS*, 2008, 22(8), 990-2.
- [112] Tenorio AR, Martinson J, Pollard D, Baum L, Landay A, “The relationship of T-regulatory cell subsets to disease stage, immune activation, and pathogen-specific immunity in HIV infection,” *Journal of acquired immune deficiency syndromes*, 2008, 48(5), 577-80.
- [113] Maek ANW, Buranapraditkun S, Klaewsongkram J, Ruxrungtham K, “Increased interleukin-17 production both in helper T cell subset Th17 and CD4-negative T cells in human immunodeficiency virus infection,” *Viral Immunol*, 2007, 20(1), 66-75.
- [114] Ciccone EJ, Greenwald JH, Lee PI, Biancotto A, Read SW, Yao MA, *et al.*, “CD4+ T cells, including Th17 and cycling subsets, are intact in the gut mucosa of HIV-1-infected long-term nonprogressors,” *J Virol*, 2011, 85(12), 5880-8.
- [115] Fazekas de St Groth B, Landay AL, “Regulatory T cells in HIV infection: pathogenic or protective participants in the immune response?,” *AIDS*, 2008, 22(6), 671-83.
- [116] Simonetta F, Bourgeois C, “CD4+FOXP3+ Regulatory T-Cell Subsets in Human Immunodeficiency Virus Infection,” *Front Immunol*, 2013.